Back to discover
Drug

Telisotuzumab vedotin

In clinical development
ClassTubulin inhibitorEmerging researchLate-stage development
RxNorm2721996ChEMBLCHEMBL3990032UNII976X9VXC3Z
1
Research papers
5
Active clinical trials
16
Protein targets
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

Clinical trial2026-08-01Primary completion · ClinicalTrials.gov

A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Clinical trial2026-07-06Results expected Q1 2028 · ClinicalTrials.gov

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Clinical trial2026-07-01Primary completion · ClinicalTrials.gov

A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Clinical trial2026-06-11Results expected Q1 2028 · ClinicalTrials.gov

A Phase II Trial of Telisotuzumab Vedotin With Osimertinib for EGFR Mutated NSCLC With c-MET Overexpression That is Progressing on Osimertinib

Clinical trial2026-04-20Results expected Q1 2027 · ClinicalTrials.gov

Phase 2, Open-Label Study in Subjects With Previously Untreated MET Amplified Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Clinical trial2024-10-28Terminated · ClinicalTrials.gov

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous <i>EGFR</i>-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.

Research2024-06-06Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Phase 3, Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Combined With Osimertinib vs Platinum-Based Chemotherapy in Subjects With c-Met Overexpressing (OE) EGFR Mutant, Locally Advanced/Metastatic Non-Squamous NSCLC After a First Progression on Prior Third Generation EGFR TKi Treatment

Clinical trial2028-04-11Withdrawn · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Telisotuzumab vedotin
RxNorm CUI
2721996
ChEMBL ID
CHEMBL3990032
UNII
976X9VXC3Z
Primary mechanism
Tubulin inhibitor

Pharmacology & targets

16 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Tubulin beta-4B chain
TUBB4B · P68371
INHIBITORTubulin inhibitor
Tubulin beta-1 chain
TUBB1 · Q9H4B7
INHIBITORTubulin inhibitor
Tubulin alpha-3C chain
TUBA3C · P0DPH7
INHIBITORTubulin inhibitor
Tubulin alpha-4A chain
TUBA4A · P68366
INHIBITORTubulin inhibitor
Tubulin beta-3 chain
TUBB3 · Q13509
INHIBITORTubulin inhibitor
Tubulin alpha-1A chain
TUBA1A · Q71U36
INHIBITORTubulin inhibitor
Tubulin beta-4A chain
TUBB4A · P04350
INHIBITORTubulin inhibitor
Tubulin beta-8 chain
TUBB8 · Q3ZCM7
INHIBITORTubulin inhibitor
Tubulin beta chain
TUBB · P07437
INHIBITORTubulin inhibitor
Tubulin alpha-1B chain
TUBA1B · P68363
INHIBITORTubulin inhibitor
Tubulin alpha-1C chain
TUBA1C · Q9BQE3
INHIBITORTubulin inhibitor
Tubulin alpha-3E chain
TUBA3E · Q6PEY2
INHIBITORTubulin inhibitor
Tubulin beta-2A chain
TUBB2A · Q13885
INHIBITORTubulin inhibitor
Tubulin beta-2B chain
TUBB2B · Q9BVA1
INHIBITORTubulin inhibitor
Tubulin beta-6 chain
TUBB6 · Q9BUF5
INHIBITORTubulin inhibitor
Hepatocyte growth factor receptor
MET · P08581
BINDING AGENTHepatocyte growth factor receptor binding agent

Clinical trials

7 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
7
registered trials across all phases
5
Active studies
3
Recruiting
2
Late-stage (III+)
2
Discontinued
PHASE DISTRIBUTIONn = 7
Phase 11Phase 24Phase 32

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes5
Carcinoma, Non-Small-Cell Lung1ErbB Receptors1Immunoconjugates1Lung Neoplasms1Proto-Oncogene Proteins c-met1
Journals, researchers & institutions
Top journals
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology1
Leading researchers
  • Ansell P1
  • Baijal S1
  • Baik C1
  • Bar J1
  • Bolotin E1
  • Bradbury P1
  • Camidge DR1
  • Cicin I1
Leading institutions
free-text, unnormalised
  • Aix Marseille University1
  • Center of Palliative Medicine De Vita1
  • Centre intégré de cancérologie de la Montérégie (CICM)1
  • College of Medicine1
  • David Geffen School of Medicine at UCLA1
  • Davidoff Cancer Center1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials